New prospects for PCSK9 inhibition

European Society of Cardiology/European Atherosclerosis Society Task Force; Ulf Landmesser; M. John Chapman; Jane K. Stock; Pierre Amarenco; Jill J. F. Belch; Jan Borén; Michel Farnier; Brian A. Ference; Stephan Gielen; Ian Graham; Diederick E. Grobbee; G. Kees Hovingh; Thomas F. Luscher; Massimo F. Piepoli; Kausik K. Ray; Erik S. Stroes; Olov Wiklund; Stephan Windecker; Jose Luis Zamorano; Fausto Pinto; Lale Tokgozoglu; Jeroen J. Bax; Alberico L. Catapano

doi:10.1093/eurheartj/ehy147

New prospects for PCSK9 inhibition

European Society of Cardiology/European Atherosclerosis Society Task Force, Ulf Landmesser (Lead / Corresponding author), M. John Chapman, Jane K. Stock, Pierre Amarenco, Jill J. F. Belch, Jan Borén, Michel Farnier, Brian A. Ference, Stephan Gielen, Ian Graham, Diederick E. Grobbee, G. Kees Hovingh, Thomas F. Luscher, Massimo F. Piepoli, Kausik K. Ray, Erik S. Stroes, Olov Wiklund, Stephan Windecker, Jose Luis ZamoranoFausto Pinto, Lale Tokgozoglu, Jeroen J. Bax, Alberico L. Catapano

Molecular and Clinical Medicine

Research output: Contribution to journal › Comment/debate › peer-review

10 Citations (Scopus)

Abstract

This commentary refers to ‘2017 update of ESC/EAS task force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia’, by U Landmesser et al., doi: 10.1093/eurheartj/ehx549.

Original language	English
Pages (from-to)	2600-2601
Number of pages	2
Journal	European Heart Journal
Volume	39
Issue number	27
Early online date	22 Mar 2018
DOIs	https://doi.org/10.1093/eurheartj/ehy147
Publication status	Published - 14 Jul 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/eurheartj/ehy147

Cite this

European Society of Cardiology/European Atherosclerosis Society Task Force, Landmesser, U., Chapman, M. J., Stock, J. K., Amarenco, P., Belch, J. J. F., Borén, J., Farnier, M., Ference, B. A., Gielen, S., Graham, I., Grobbee, D. E., Hovingh, G. K., Luscher, T. F., Piepoli, M. F., Ray, K. K., Stroes, E. S., Wiklund, O., Windecker, S., ... Catapano, A. L. (2018). New prospects for PCSK9 inhibition. European Heart Journal, 39(27), 2600-2601. https://doi.org/10.1093/eurheartj/ehy147

@article{e89d5cae708248dd826dd317c48bec50,

title = "New prospects for PCSK9 inhibition",

abstract = "This commentary refers to {\textquoteleft}2017 update of ESC/EAS task force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia{\textquoteright}, by U Landmesser et al., doi: 10.1093/eurheartj/ehx549.",

author = "{European Society of Cardiology/European Atherosclerosis Society Task Force} and Ulf Landmesser and Chapman, {M. John} and Stock, {Jane K.} and Pierre Amarenco and Belch, {Jill J. F.} and Jan Bor{\'e}n and Michel Farnier and Ference, {Brian A.} and Stephan Gielen and Ian Graham and Grobbee, {Diederick E.} and Hovingh, {G. Kees} and Luscher, {Thomas F.} and Piepoli, {Massimo F.} and Ray, {Kausik K.} and Stroes, {Erik S.} and Olov Wiklund and Stephan Windecker and Zamorano, {Jose Luis} and Fausto Pinto and Lale Tokgozoglu and Bax, {Jeroen J.} and Catapano, {Alberico L.}",

year = "2018",

month = jul,

day = "14",

doi = "10.1093/eurheartj/ehy147",

language = "English",

volume = "39",

pages = "2600--2601",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford University Press",

number = "27",

}

European Society of Cardiology/European Atherosclerosis Society Task Force, Landmesser, U, Chapman, MJ, Stock, JK, Amarenco, P, Belch, JJF, Borén, J, Farnier, M, Ference, BA, Gielen, S, Graham, I, Grobbee, DE, Hovingh, GK, Luscher, TF, Piepoli, MF, Ray, KK, Stroes, ES, Wiklund, O, Windecker, S, Zamorano, JL, Pinto, F, Tokgozoglu, L, Bax, JJ & Catapano, AL 2018, 'New prospects for PCSK9 inhibition', European Heart Journal, vol. 39, no. 27, pp. 2600-2601. https://doi.org/10.1093/eurheartj/ehy147

TY - JOUR

T1 - New prospects for PCSK9 inhibition

AU - European Society of Cardiology/European Atherosclerosis Society Task Force

AU - Landmesser, Ulf

AU - Chapman, M. John

AU - Stock, Jane K.

AU - Amarenco, Pierre

AU - Belch, Jill J. F.

AU - Borén, Jan

AU - Farnier, Michel

AU - Ference, Brian A.

AU - Gielen, Stephan

AU - Graham, Ian

AU - Grobbee, Diederick E.

AU - Hovingh, G. Kees

AU - Luscher, Thomas F.

AU - Piepoli, Massimo F.

AU - Ray, Kausik K.

AU - Stroes, Erik S.

AU - Wiklund, Olov

AU - Windecker, Stephan

AU - Zamorano, Jose Luis

AU - Pinto, Fausto

AU - Tokgozoglu, Lale

AU - Bax, Jeroen J.

AU - Catapano, Alberico L.

PY - 2018/7/14

Y1 - 2018/7/14

N2 - This commentary refers to ‘2017 update of ESC/EAS task force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia’, by U Landmesser et al., doi: 10.1093/eurheartj/ehx549.

AB - This commentary refers to ‘2017 update of ESC/EAS task force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia’, by U Landmesser et al., doi: 10.1093/eurheartj/ehx549.

U2 - 10.1093/eurheartj/ehy147

DO - 10.1093/eurheartj/ehy147

M3 - Comment/debate

C2 - 29579192

SN - 0195-668X

VL - 39

SP - 2600

EP - 2601

JO - European Heart Journal

JF - European Heart Journal

IS - 27

ER -

New prospects for PCSK9 inhibition

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this